However, inhibiting both pathways, represented by administration of PARP inhibitors in BRCA1/2-mutated cancers, prevents both DNA repair machineries, resulting in unrepairable DNA damage and subsequent cell death of the mutated cancer cells [32,33]. This evidence concerns the gene BRCA1 and cancer.